» Articles » PMID: 29088719

The Downregulation of Putative Anticancer Target BORIS/CTCFL in an Addicted Myeloid Cancer Cell Line Modulates the Expression of Multiple Protein Coding and NcRNA Genes

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Nov 2
PMID 29088719
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The gene, is a testis-specific paralog frequently erroneously activated in cancer, although its exact role in cancer remains unclear. BORIS is both a transcription factor and an architectural chromatin protein. BORIS' normal role is to establish a germline-like gene expression and remodel the epigenetic landscape in testis; it similarly remodels chromatin when activated in human cancer. Critically, at least one cancer cell line, K562, is dependent on BORIS for its self-renewal and survival. Here, we downregulate BORIS expression in the K562 cancer cell line to investigate downstream pathways regulated by BORIS. RNA-seq analyses of both mRNA and small ncRNAs, including miRNA and piRNA, in the knock-down cells revealed a set of differentially expressed genes and pathways, including both testis-specific and general proliferation factors, as well as proteins involved in transcription regulation and cell physiology. The differentially expressed genes included important transcriptional regulators such as and . Data indicate that both direct binding of BORIS to promoter regions and locus-control activity via long-distance chromatin domain regulation are involved. The sum of findings suggests that activation in leukemia does not just recapitulate the germline, but creates a unique regulatory network.

Citing Articles

Predicting splicing patterns from the transcription factor binding sites in the promoter with deep learning.

Lin T, Tsai C, Shiau C, Huang J, Tsai H BMC Genomics. 2024; 25(Suppl 3):830.

PMID: 39227799 PMC: 11373144. DOI: 10.1186/s12864-024-10667-7.


BORIS/CTCFL epigenetically reprograms clustered CTCF binding sites into alternative transcriptional start sites.

Pugacheva E, Bhatt D, Rivero-Hinojosa S, Tajmul M, Fedida L, Price E Genome Biol. 2024; 25(1):40.

PMID: 38297316 PMC: 10832218. DOI: 10.1186/s13059-024-03175-0.


Discovering a binary CTCF code with a little help from BORIS.

Lobanenkov V, Zentner G Nucleus. 2017; 9(1):33-41.

PMID: 29077515 PMC: 5973138. DOI: 10.1080/19491034.2017.1394536.

References
1.
Majid S, Dar A, Saini S, Chen Y, Shahryari V, Liu J . Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. Cancer Res. 2010; 70(7):2809-18. DOI: 10.1158/0008-5472.CAN-09-4176. View

2.
Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi J . Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer. J Biol Chem. 2012; 287(21):17386-17397. PMC: 3366838. DOI: 10.1074/jbc.M111.321158. View

3.
Agatheeswaran S, Pattnayak N, Chakraborty S . Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells. Sci Rep. 2016; 6:32493. PMC: 5009428. DOI: 10.1038/srep32493. View

4.
Rasko J, Wong J . Nuclear microRNAs in normal hemopoiesis and cancer. J Hematol Oncol. 2017; 10(1):8. PMC: 5217201. DOI: 10.1186/s13045-016-0375-x. View

5.
Wang K, Xu Z, Wang N, Tian Y, Sun X, Ma Y . Analysis of microRNA and gene networks in human chronic myelogenous leukemia. Mol Med Rep. 2015; 13(1):453-60. DOI: 10.3892/mmr.2015.4502. View